Full-Time

Associate Director, Senior Solution Delivery Partner

Commercial IT, Market Access

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$169.2k - $253k/yr

+ Incentive opportunity

Princeton, NJ, USA

Remote

Up to 20% travel is required based on business needs.

Bachelor's

Category
IT Operations (1)
Required Skills
Power BI
Microsoft Azure
Agile
SQL
CRM
JIRA
Snowflake

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • At least 10 years of overall experience.
  • At least 5 years of technical experience with hands-on work in at least two pharmaceutical sales and marketing technologies.
  • Experience with commercial data warehouses, including Snowflake and SQL.
  • Experience with data sources such as IQVIA, Precision, and MMIT.
  • Experience with field reporting and commercial analytics using Power BI or similar tools.
  • At least 5 years of commercial domain experience in a technology role supporting market access, pricing and contracting, channel strategy, and/or commercial operations.
  • Strong knowledge of business analysis, process design, documentation, and critical thinking.
  • Experience supporting commercial teams, including brand, sales, market access, and/or commercial operations teams, in a technology role involving business analysis, requirements gathering, and solution identification and presentation.
  • Experience working with globally distributed business and information technology teams, especially in Japan, the European Union, and India.
  • Strong collaboration skills for working with stakeholders and platform teams to scope activities and identify solutions.
  • Strong communication, negotiation, and presentation skills.
  • A minimum of a bachelor's degree.
  • Willingness to travel up to 20% based on business needs.
Responsibilities
  • Collaborate with functional leaders to identify, qualify, and drive adoption of technology solutions that achieve business operational outcomes and strategic goals.
  • Coordinate across shared services groups within information technology and other functions to implement, align, integrate, and enable new capabilities for Otsuka and its affiliates.
  • Identify technology opportunities using the information technology strategy and roadmap, address process pain points, enable leading practices and technology improvements, and build business cases for information technology initiatives.
  • Create and own business-aligned documents and implementation plans.
  • Prepare, lead, and document requirements-gathering efforts.
  • Decompose abstract and complex concepts into business and functional requirements.
  • Develop business cases with solution recommendations, evaluate and qualify opportunities, and define measurable business outcomes.
  • Lead and manage projects from inception to completion.
  • Develop project plans, timelines, and budgets; identify risks; provide progress updates; and support stakeholder communications.
  • Coordinate with cross-functional teams to deliver solutions on time and successfully.
  • Plan, coordinate, and support user acceptance testing and defect resolution with business stakeholders.
  • Work with technical and testing teams to design and implement scalable, sustainable solutions aligned with business requirements, industry best practices, and technology strategies.
  • Maintain comprehensive project documentation, including project plans, status reports, system documentation, and post-implementation reviews.
  • Provide techno-functional knowledge to evaluate business-process improvements and execution.
  • Maintain awareness of industry trends and provide recommendations that support decision-making across three or more functional areas.
  • Use business-process and information-technology capability awareness to align solution decisions with business priorities.
  • Determine which internal information-technology products and services should be engaged to deliver technology solutions and business value.
  • Guide business partners toward standard platform solutions.
  • Lead vendor evaluation, selection, and relationship management during project execution, with oversight from the business-partner area lead.
  • Create, contract, and manage project finances with the business partner and hold vendors accountable for contractual delivery.
Desired Qualifications
  • Experience with pricing and contracting data and processes.
  • Experience with market access data and analytics reporting.
  • Experience with revenue management processes and automation.
  • Experience with customer relationship management for market access account-management teams.
  • Knowledge of technology trends and best practices that improve processes and strategic decision-making in supported areas.
  • Experience with emerging artificial intelligence solutions and defining use cases for commercial teams.
  • Experience with Agile methodologies such as Scaled Agile.
  • Experience managing demand backlogs using tools such as Azure DevOps, Jira, or Monday.com.
  • Data or solution architecture experience.
  • Experience supporting pharmaceutical product-launch activities in a technology role.
  • A degree in Computer Science, Engineering, or an adjacent field.
  • An advanced degree in sciences, business administration, or pharmaceuticals.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT’s July 2026 VISIONARY data showed two-year eGFR stabilization and kidney-failure risk reduction.
  • SIMTRIYO cleared FDA review on July 24, 2026, opening a large ADHD market.
  • Japan covered Paradise renal denervation on March 1, 2026, accelerating cardiovascular device revenue.

What critics are saying

  • VOYXACT remains accelerated-approval dependent until the FDA accepts its confirmatory 2026 traditional filing.
  • SIMTRIYO cannot launch until DEA scheduling, delaying cash collection and ceding early prescriptions.
  • Otsuka still depends on a few launches; VOYXACT failure or Simtriyo slowdown would crush growth.

What makes Otsuka Pharmaceutical unique

  • SIMTRIYO became Otsuka’s first U.S. ADHD launch, expanding its CNS franchise on July 24, 2026.
  • VOYXACT gave Otsuka first U.S. APRIL inhibition and traditional-approval runway in IgAN.
  • Astex’s fragment-based platform secured Genentech’s breast-cancer pact on July 6, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.